New combo aims to deepen remission in Tough-to-Treat myeloma
NCT ID NCT05801939
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a drug called cevostamab after standard CAR T cell therapy can help people with relapsed or refractory multiple myeloma achieve a deeper remission. About 30 adults who have already received CAR T cells will get cevostamab infusions every 3 weeks for up to 8 cycles. The main goal is to see if more patients become cancer-free at the 12-month mark.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat myeloma
- Can engineered immune cells outsmart Treatment-Resistant myeloma?
- Can a lower dose of a myeloma drug keep the disease in check with fewer side effects?
- A pre-treatment pill may supercharge cancer-fighting immune cells
- New antibody combo aims to stall multiple Myeloma's return
- Real-World data may reveal best Second-Line therapy for multiple myeloma